Research programme: selective nicotinic acetylcholine receptor antagonists - Suven Life Sciences

Drug Profile

Research programme: selective nicotinic acetylcholine receptor antagonists - Suven Life Sciences

Latest Information Update: 24 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suven Life Sciences
  • Class
  • Mechanism of Action Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Major depressive disorder

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 18 Oct 2016 Suven Life Sciences has patent protection for selective alpha-4-beta-2 receptor and H3 Inverse agonists for the treatment of major depressive disorder in Europe and Israel
  • 29 Jun 2016 Suven Life Sciences has patent protection for selective alpha-4-beta-2 receptor antagonists in Eurasia
  • 29 Dec 2015 Suven Life Sciences has patent protection for alpha-4-beta-2 compounds for the treatment of major depressive disorder in Europe and Macau
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top